PPARA and metabolic dysfunction-associated steatotic liver disease: Elafibranor (GFT505) was studied in animal models of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) and liver fibrosis; according to Staels et al. [20], GFT505 decreases the plasma concentration of the hepatic enzyme (such as ALT, AST), decreases hepatic lipid storage and inhibits proinflammatory (IL-1, TNFα) and profibrotic gene expression with PPARα-dependent and independent mechanisms.